Edgewise Therapeutics Q3 2026 Results: Turns Profitable, Net Income $1.17B
Edgewise Therapeutics reported 109,482,763 shares of common stock outstanding as of October 31, 2026. The company is focusing its resources on the development of EDG-7500 and EDG-15400 following the Sevasemten Sale, which has impacted its operating expenses and cash position.
- Key figure
- Net income $1.17B